Russell Investments Group Ltd. Acquires 51,730 Shares of Phreesia, Inc. $PHR

Key Points

• Russell Investments Group Ltd. has increased its stake in Phreesia, Inc. by 35.4% to 197,848 shares, valued at approximately $5 million.
• Institutional investors and hedge funds own 92.10% of Phreesia's stock, with significant stakes also acquired by Vanguard and Deerfield Management.
• Phreesia reported a quarterly earnings per share of ($0.07), exceeding analysts' expectations and showing a revenue increase of 14.5% year-over-year.

Russell Investments Group Ltd. boosted its stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 35.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 197,848 shares of the company's stock after buying an additional 51,730 shares during the period. Russell Investments Group Ltd. owned about 0.34% of Phreesia worth $5,057,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Phreesia by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock worth $126,177,000 after buying an additional 113,405 shares during the period. Deerfield Management Company L.P. Series C raised its holdings in Phreesia by 133.6% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company's stock worth $31,999,000 after buying an additional 727,384 shares during the period. Millennium Management LLC raised its holdings in Phreesia by 83.2% during the 4th quarter. Millennium Management LLC now owns 653,634 shares of the company's stock worth $16,445,000 after buying an additional 296,863 shares during the period. Northern Trust Corp raised its holdings in Phreesia by 6.6% during the 4th quarter. Northern Trust Corp now owns 571,807 shares of the company's stock worth $14,387,000 after buying an additional 35,392 shares during the period. Finally, Nuveen LLC acquired a new stake in Phreesia during the 1st quarter worth about $14,206,000. Institutional investors and hedge funds own 92.10% of the company's stock.

Analysts Set New Price Targets

PHR has been the topic of several research analyst reports. DA Davidson raised Phreesia to a "strong-buy" rating in a research note on Tuesday, July 22nd. Canaccord Genuity Group lowered their target price on Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a research note on Thursday, May 29th. Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Citigroup reaffirmed a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Finally, KeyCorp lifted their target price on Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, Phreesia presently has a consensus rating of "Buy" and a consensus price target of $32.27.

Phreesia Stock Up 2.1%

Shares of NYSE PHR traded up $0.61 during trading hours on Monday, hitting $30.36. The stock had a trading volume of 1,047,812 shares, compared to its average volume of 523,506. The company has a market capitalization of $1.81 billion, a P/E ratio of -41.03 and a beta of 0.71. The firm's 50-day moving average price is $27.49 and its two-hundred day moving average price is $26.39. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $31.04. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.06. The business had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%.The firm's quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.05) EPS. Phreesia has set its FY 2026 guidance at EPS. Analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insiders Place Their Bets

In other Phreesia news, Director Mark Douglas Smith sold 7,000 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $29.00, for a total transaction of $203,000.00. Following the completion of the sale, the director owned 37,353 shares of the company's stock, valued at $1,083,237. This represents a 15.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 1,245 shares of the company's stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $26.89, for a total value of $33,478.05. Following the sale, the general counsel directly owned 136,978 shares of the company's stock, valued at $3,683,338.42. The trade was a 0.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 53,882 shares of company stock worth $1,513,007 in the last quarter. Corporate insiders own 5.50% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.